Correction to: Solving patients with rare diseases through programmatic reanalysis of genome-phenome data
Giorgio Casari(IRCCS Ospedale San Raffaele), Elisa Benetti(University of Siena), Isabelle Nelson(University of Bonn), Christian Gilissen(Radboud University Nijmegen), Richarda M. de Voer(Radboud University Nijmegen), Matthis Synofzik(German Center for Neurodegenerative Diseases), Gabriel Capellá(Institut Català d'Oncologia), Lisenka E.L.M. Vissers(Radboud University Nijmegen), José Garcia‐Pelaez(Universidade do Porto), Evelin Schröck(German Cancer Research Center), Carles Hernandéz-Ferrer(Barcelona Supercomputing Center), Leslie Matalonga(Centre for Genomic Regulation), Joeri K. van der Velde(University Medical Center Groningen), Marc Tischkowitz(University of Cambridge), Sophia Peters(University of Bonn), Siddharth Banka(University of Manchester), Antonio Vitobello(Inserm), Carla Oliveíra(Universidade do Porto), Ana Töpf(NIHR Newcastle Biomedical Research Centre), Verena Steinke‐Lange(University of Cambridge), Laura Valle(Institut d'Investigació Biomédica de Bellvitge), Marco Savarese(Folkhälsans Forskningscentrum), D. Gareth Evans(Manchester Academic Health Science Centre), Rebecca Schüle(Heidelberg University), Shuang� Li(Northwest A&F University), Peter Robinson(Jackson Laboratory), Yannis Duffourd(Radboud University Nijmegen), Karolis Sablauskas(University of Helsinki), Prasanth Sivakumar(Jackson Laboratory), Stefan Aretz(University of Bonn), Davide Piscia(Centre for Genomic Regulation), Isabel Cuesta(Instituto de Salud Carlos III), Anna Katharina Sommer(University of Bonn)
Cited by 1
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
|JNCI Journal of the National Cancer Institute|2013|946
Germline <i>BRCA</i> Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
|Journal of Clinical Oncology|2013|833